Home›Trial›NCT05618379
NCT05618379ACTIVE NOT RECRUITING

Adult Spinal Muscular Atrophy (SMA) China Registry

Study Summary

The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

Conditions
Muscular Atrophy, Spinal
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
BIIB
Biogen Inc
Neuroscience
D43/100
Study Details
Enrollment200 participants
Primary Completion—
Lead SponsorBiogen
Data Retrieved2026-04-11 02:55:21.687227+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 200 participants
Sponsor Catalyst Profile

Biogen Inc (BIIB) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BIIB Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.